Objective: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are gastrointestinal disorders, which can be triggered by gut microbiota dysbiosis. The development of IBS-like symptoms has been linked to the overgrowth of spp. In addition, the critical role of fungi has been highlighted in the pathogenesis of IBD. This study investigated the association between and selected yeasts in IBS and IBD patients.
Methods: This investigation is a cross-sectional study from 2022 to 2024, performed on 91 participants, including 20 healthy individuals, 27 patients with IBS, and 44 IBD patients [39 with ulcerative colitis (UC; 88.63%) and 5 (11.37%) Crohn's disease (CD)], who were also categorized based on the presence of . Total DNA was extracted from stool samples, and the presence and quantity of yeasts including spp., , and were evaluated by real-time PCR. Statistical tests were used to assess significant associations between variables.
Results: and were the most prevalent yeasts in all groups. and were identified in neither patients nor healthy subjects. The presence/absence of was not significantly different between patients with IBD, IBS, and the control groups. This was similar for . However, there was a difference in the presence of among patients, although it was insignificant (-value = 0.077). There was a significant difference in the quantity of between IBD (880.421 ± 2140.504), IBS (10.307 ± 15.206), and controls (2875.888 ± 8383.889) (-value = 0.020). Specifically, the source of difference was seen between IBD patients and the control group (-value = 0.005). In addition, considering the presence of , a statistically significant association was seen between the number of and the sample groups (-value = 0.013). The quantity of was significantly different between IBS and IBD patients.
Conclusion: Regarding the presence of , the quantity of and was increased and decreased in the studied groups, respectively. This is a preliminary study, and eukaryote-eukaryote association in IBS and IBD patients should be considered in further studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865192 | PMC |
| http://dx.doi.org/10.3389/fmed.2025.1514587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Habitual Intake of Macronutrients and Fermentable Oligo-, Di-, Monosaccharides and Polyols is not associated with Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease.
Clin Nutr ESPEN
March 2025
Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Purpose: Almost a third of patients with inactive inflammatory bowel disease (IBD) suffer from symptoms compatible with irritable bowel syndrome (IBS-like symptoms). The relation between these symptoms and diet in patients with IBD is not fully established. We aimed to assess associations between IBS-like symptoms and intake of macronutrients and fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs) in patients with inactive IBD compared to an IBD-free background population.
View Article and Find Full Text PDFPrevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort).
Inflamm Bowel Dis
March 2025
Telemark Hospital Trust, Department of Gastroenterology, Skien, Norway.
Background: Distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) flare-ups is challenging. This study used objective remission markers to accurately determine IBS prevalence in a population-based cohort of patients with IBD.
Methods: Adults with ulcerative colitis and Crohn's disease were recruited from the IBD in South-Eastern Norway III cohort study.
A preliminary study of the association between and quantification of selected yeasts in IBD and IBS patients.
Front Med (Lausanne)
February 2025
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Objective: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are gastrointestinal disorders, which can be triggered by gut microbiota dysbiosis. The development of IBS-like symptoms has been linked to the overgrowth of spp. In addition, the critical role of fungi has been highlighted in the pathogenesis of IBD.
View Article and Find Full Text PDFAdvances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
Adv Sci (Weinh)
February 2025
Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, China Medical University, Liao Ning, Shen Yang, 110032, P. R. China.
This article provides an overview of the advancements in the application of fecal microbiota transplantation (FMT) in treating diseases related to intestinal dysbiosis. FMT involves the transfer of healthy donor fecal microbiota into the patient's body, aiming to restore the balance of intestinal microbiota and thereby treat a variety of intestinal diseases such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), constipation, short bowel syndrome (SBS), and irritable bowel syndrome (IBS). While FMT has shown high efficacy in the treatment of rCDI, further research is needed for its application in other chronic conditions.
View Article and Find Full Text PDFPerspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Pharmaceuticals (Basel)
January 2025
Department of Chemical-Biological and Agricultural Sciences, Universidad de Sonora, Unidad Regional Norte, Caborca 83621, Mexico.
Berberine is a promising agent for modulating the intestinal microbiota, playing a crucial role in human health homeostasis. This natural compound promotes the growth of beneficial bacteria such as , , and while reducing harmful bacteria such as . Clinical and preclinical studies demonstrate that Berberine helps regulate T2D and metabolic disorders, improves blood glucose levels during T2D, and reduces lipid profile and chronic inflammation, especially when combined with probiotics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!